1. Home
  2. FSK vs NAMS Comparison

FSK vs NAMS Comparison

Compare FSK & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FS KKR Capital Corp.

FSK

FS KKR Capital Corp.

N/A

Current Price

$10.29

Market Cap

4.2B

Sector

Finance

ML Signal

N/A

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

N/A

Current Price

$30.09

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSK
NAMS
Founded
2007
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.5B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
FSK
NAMS
Price
$10.29
$30.09
Analyst Decision
Hold
Strong Buy
Analyst Count
8
8
Target Price
$14.63
$46.75
AVG Volume (30 Days)
4.6M
809.4K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
19.23%
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$25.64
Revenue Next Year
N/A
$530.85
P/E Ratio
$261.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.16
$14.06
52 Week High
$22.68
$42.00

Technical Indicators

Market Signals
Indicator
FSK
NAMS
Relative Strength Index (RSI) 22.37 37.63
Support Level $10.28 $23.48
Resistance Level $16.05 $37.43
Average True Range (ATR) 0.47 1.75
MACD -0.09 -0.37
Stochastic Oscillator 4.05 12.69

Price Performance

Historical Comparison
FSK
NAMS

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: